FIT BIOTECH OY
Company announcement
September 5, 2016 at 15:15 EET
FIT Biotech will publish half-year financial report on September 14, 2016
FIT Biotech Oy will publish half-year financial report already on September 14, 2016 instead of September 15, 2016 as earlier announced.
FIT Biotech’s Extraordinary General Meeting (EGM) will be held on September 15, 2016 starting at 11:00 as informed in the company’s announcement published on August 25, 2016.
FIT BIOTECH OY
Further information:
Chairman of the Board, Juha Vapaavuori
Email: juha.vapaavuori@fitbiotech.com
Tel: +358 50 372 0824
Certified Advisor: Translink Corporate Finance Oy, tel. +358 20 743 2790
FIT Biotech in brief
FIT Biotech Oy is a biotechnology company established in 1995 that develops and licenses its patented GTU® (Gene Transport Unit) vector technology for new-generation medical treatments. GTU® is a gene transport technology that meets an important medical challenge in the usability of gene therapy and DNA vaccines.
FIT Biotech applies GTU® technology in its drug development programmes. Application areas include cancer (gene therapy) and infectious diseases such as HIV and tuberculosis, as well as animal vaccines.
FIT Biotech shares are listed on the First North Finland market maintained by Nasdaq Helsinki Oy.
DISTRIBUTION:
Nasdaq Helsinki
Principal media
www.fitbiotech.com
